Pediatric Moyamoya Biomarkers: Narrowing the Knowledge Gap

IF 2.4 4区 医学 Q2 CLINICAL NEUROLOGY Seminars in Pediatric Neurology Pub Date : 2022-10-01 DOI:10.1016/j.spen.2022.101002
Laura L. Lehman , Matsanga Leyila Kaseka , Jeffery Stout , Alfred P. See , Lisa Pabst , Lisa R. Sun , Sahar A. Hassanein , Michaela Waak , Arastoo Vossough , Edward R. Smith , Nomazulu Dlamini
{"title":"Pediatric Moyamoya Biomarkers: Narrowing the Knowledge Gap","authors":"Laura L. Lehman ,&nbsp;Matsanga Leyila Kaseka ,&nbsp;Jeffery Stout ,&nbsp;Alfred P. See ,&nbsp;Lisa Pabst ,&nbsp;Lisa R. Sun ,&nbsp;Sahar A. Hassanein ,&nbsp;Michaela Waak ,&nbsp;Arastoo Vossough ,&nbsp;Edward R. Smith ,&nbsp;Nomazulu Dlamini","doi":"10.1016/j.spen.2022.101002","DOIUrl":null,"url":null,"abstract":"<div><p><span>Moyamoya is a progressive cerebrovascular disorder that leads to stenosis of the arteries in the distal internal carotid, proximal middle cerebral and proximal </span>anterior cerebral arteries<span><span><span> of the circle of Willis. Typically a network of collaterals form to bypass the stenosis and maintain cerebral blood flow. As moyamoya progresses it affects the anterior circulation more commonly than posterior circulation, and cerebral blood flow becomes increasingly reliant on external carotid supply. Children with moyamoya are at increased risk for ischemic symptoms including stroke and </span>transient ischemic attacks (TIA). In addition, cognitive decline may occur over time, even in the absence of clinical stroke. Standard of care for stroke prevention in children with symptomatic moyamoya is </span>revascularization<span> surgery. Treatment<span> of children with asymptomatic moyamoya with revascularization surgery however remains more controversial. Therefore, biomarkers are needed to assist with not only diagnosis but also with determining ischemic risk and identifying best surgical candidates. In this review we will discuss the current knowledge as well as gaps in research in relation to pediatric moyamoya biomarkers including neurologic presentation, cognitive, neuroimaging, genetic and biologic biomarkers of disease severity and ischemic risk.</span></span></span></p></div>","PeriodicalId":49284,"journal":{"name":"Seminars in Pediatric Neurology","volume":"43 ","pages":"Article 101002"},"PeriodicalIF":2.4000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Pediatric Neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S107190912200050X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Moyamoya is a progressive cerebrovascular disorder that leads to stenosis of the arteries in the distal internal carotid, proximal middle cerebral and proximal anterior cerebral arteries of the circle of Willis. Typically a network of collaterals form to bypass the stenosis and maintain cerebral blood flow. As moyamoya progresses it affects the anterior circulation more commonly than posterior circulation, and cerebral blood flow becomes increasingly reliant on external carotid supply. Children with moyamoya are at increased risk for ischemic symptoms including stroke and transient ischemic attacks (TIA). In addition, cognitive decline may occur over time, even in the absence of clinical stroke. Standard of care for stroke prevention in children with symptomatic moyamoya is revascularization surgery. Treatment of children with asymptomatic moyamoya with revascularization surgery however remains more controversial. Therefore, biomarkers are needed to assist with not only diagnosis but also with determining ischemic risk and identifying best surgical candidates. In this review we will discuss the current knowledge as well as gaps in research in relation to pediatric moyamoya biomarkers including neurologic presentation, cognitive, neuroimaging, genetic and biologic biomarkers of disease severity and ischemic risk.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿科烟雾病生物标志物:缩小知识差距
烟雾病是一种进行性脑血管疾病,可导致颈内动脉远端、大脑中动脉近端和大脑前动脉近端威利斯圈动脉狭窄。通常会形成一个络络来绕过狭窄并维持脑血流量。随着烟雾的进展,它对前循环的影响比后循环更常见,脑血流越来越依赖于颈外动脉供应。患有烟雾病的儿童出现缺血性症状的风险增加,包括中风和短暂性脑缺血发作(TIA)。此外,随着时间的推移,即使在没有临床中风的情况下,认知能力也会下降。有症状烟雾症的儿童中风预防的标准护理是血管重建术。然而,对无症状烟雾的儿童进行血管重建术治疗仍存在争议。因此,不仅需要生物标志物来辅助诊断,还需要生物标志物来确定缺血风险和确定最佳手术候选人。在这篇综述中,我们将讨论目前的知识以及与儿童烟雾病生物标志物相关的研究差距,包括神经学表现、认知、神经影像学、疾病严重程度和缺血性风险的遗传和生物学生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in Pediatric Neurology
Seminars in Pediatric Neurology CLINICAL NEUROLOGY-PEDIATRICS
CiteScore
4.80
自引率
0.00%
发文量
38
审稿时长
84 days
期刊介绍: Seminars in Pediatric Neurology is a topical journal that focuses on subjects of current importance in the field of pediatric neurology. The journal is devoted to making the status of such topics and the results of new investigations readily available to the practicing physician. Seminars in Pediatric Neurology is of special interest to pediatric neurologists, pediatric neuropathologists, behavioral pediatricians, and neurologists who treat all ages.
期刊最新文献
Ataxia telangiectasia Chedíak-Higashi Syndrome: Hair-to-toe spectrum Hereditary hemorrhagic telangiectasia: A pediatric-focused review Neurofibromatosis type 1 - an update Neurofibromatosis type 2-related schwannomatosis - An update
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1